| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 51 |
| 1 | PEMBROLIZUMAB | 46 |
| 2 | IPILIMUMAB | 28 |
| 3 | CARBOPLATIN | 25 |
| 4 | PACLITAXEL | 19 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 18 |
| 6 | CAPECITABINE | 8 |
| 7 | OXALIPLATIN | 8 |
| 8 | PEMETREXED DISODIUM | 8 |
| 9 | PEMETREXED | 6 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CEFACLOR | 1 | 0.0006 |
| 1 | IPILIMUMAB | 28 | 0.0006 |
| 2 | RAMUCIRUMAB | 4 | 0.0006 |
| 3 | NIVOLUMAB | 51 | 0.0005 |
| 4 | AVELUMAB | 2 | 0.0005 |
| 5 | PEMBROLIZUMAB | 46 | 0.0004 |
| 6 | DOSTARLIMAB | 1 | 0.0004 |
| 7 | DECITABINE | 1 | 0.0002 |
| 8 | TREMELIMUMAB | 1 | 0.0002 |
| 9 | PEMETREXED DISODIUM | 8 | 0.0002 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 100 | 0.0010 |
| 1 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 4 | 0.0006 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 29 | 0.0006 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 3 | 0.0001 |
| 4 | Platinum-based Drug [EPC] | 35 | 0.0001 |
| 5 | Microtubule Inhibitor [EPC] | 19 | 0.0001 |
| 6 | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | 1 | 0.0000 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 13 | 0.0000 |
| 8 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 1 | 0.0000 |
| 9 | Folate Analog Metabolic Inhibitor [EPC] | 6 | 0.0000 |